Content about Rhinitis

April 3, 2013
FDA approves new allergy drug for children

The Food and Drug Administration has approved a new drug for allergies in children made by Tris Pharma, the drug maker said.

MONMOUTH JUNCTION, N.J. — The Food and Drug Administration has approved a new drug for allergies in children made by Tris Pharma, the drug maker said Wednesday.

Tris announced the approval of Karbinal ER (carbinoxamine maleate) extended-release oral suspension in the 4 mg-per-five milliliter strength. The company said the drug was the first sustained-release histamine receptor blocking agent for seasonal and perennial allergic rhinitis in children 2 and older.

February 25, 2013
Spring forecast: Increase in allergy symptoms

As spring approaches, people with allergies can blame global warming for some of their suffering, according to the American College of Allergy, Asthma and Immunology. Weather conditions have a significant effect on the levels of pollen and mold in the air, which affects the severity of allergies.

As spring approaches, people with allergies can blame global warming for some of their suffering, according to the American College of Allergy, Asthma and Immunology. Weather conditions have a significant effect on the levels of pollen and mold in the air, which affects the severity of allergies.

That suggests mold allergens could be particularly prominent this spring given the extent of drought across the United States — dry and hot weather lifts molds from the soil to be carried by the air. In addition to tree pollen, springtime mold contributes to hay fever.

November 29, 2012
ReportersNotebook — Over the Counter, 12/10/12

Valeant Consumer Products recently announced that its line of Ocean Saline Nasal Sprays have been the most recommended by pharmacists for 15 years running. 


SUPPLIER NEWS — Valeant Consumer Products recently announced that its line of Ocean Saline Nasal Sprays have been the most recommended by pharmacists for 15 years running. 


Ocean offers nonmedicated relief from dry and irritated nasal passages due to allergies, colds, flu, sinusitis and rhinitis. The nasal spray is gentle enough for infants and has three delivery options — standing the bottle upright delivers a spray; horizontally, a stream; and upside-down, a drop. 


November 8, 2012
Valeant Consumer Products: Ocean Saline Nasal Sprays most recommended by pharmacists for 15 years

Valeant Consumer Products recently announced that its line of Ocean Saline Nasal Sprays has been the most recommended by pharmacists for 15 years running.

BRIDGEWATER, N.J. — Valeant Consumer Products recently announced that its line of Ocean Saline Nasal Sprays has been the most recommended by pharmacists for 15 years running. 

Ocean offers nonmedicated relief from dry and irritated nasal passages due to allergies, colds, flu, sinusitis and rhinitis. The nasal spray is gentle enough for infants and has three delivery options — standing the bottle upright delivers a spray; horizontally, a stream; and upside-down, a drop. 

August 16, 2012
American College of Allergy, Asthma and Immunology dispels fall allergy myths

According to the American College of Allergy, Asthma and Immunology, 25 million adults and children across the country were diagnosed with rhinitis, or hay fever, within the last 12 months, which may lead many to believe they’ve caught an early-season cold.

ARLINGTON HEIGHTS, Ill. — According to the American College of Allergy, Asthma and Immunology, 25 million adults and children across the country were diagnosed with rhinitis, or hay fever, within the last 12 months, which may lead many to believe they’ve caught an early-season cold.

March 26, 2012
FDA approves Teva allergy drug

The Food and Drug Administration has approved a drug made by Teva for treating allergies, the company said Monday.

JERUSALEM — The Food and Drug Administration has approved a drug made by Teva for treating allergies, the company said Monday.

Teva announced the approval of Qnasl (beclomethasone dipropionate) for seasonal and year-round nasal allergies in patients ages 12 years and older. The company said the drug, a "dry" nasal aerosol, would become available next month.

February 24, 2012
ACAAI: Five factors that can help delay allergy relief this spring

In preparation for spring, the American College of Allergy, Asthma and Immunology on Friday noted that avoiding certain fruits and vegetables, installing the proper air filters, closing the windows, filling any allergy prescriptions and consulting with an allergist can all prevent the delay of allergy symptom relief for more than 35 million Americans who suffer from seasonal allergies.

ARLINGTON HEIGHTS, Ill. — In preparation for spring, the American College of Allergy, Asthma and Immunology on Friday noted that avoiding certain fruits and vegetables, installing the proper air filters, closing the windows, filling any allergy prescriptions and consulting with an allergist can all prevent the delay of allergy symptom relief for more than 35 million Americans who suffer from seasonal allergies.

August 8, 2011
FDA accepts Teva approval application for BDP Nasal HFA

The Food and Drug Administration has accepted an approval application for a drug made by Teva Pharmaceutical Industries for treating allergies, Teva said.

JERUSALEM — The Food and Drug Administration has accepted an approval application for a drug made by Teva Pharmaceutical Industries for treating allergies, Teva said.

The Israeli drug maker said the FDA accepted its application for BDP Nasal HFA (beclomethasone dipropionate hydrofluoroalkane) for the treatment of seasonal allergic rhinitis and perennial allergic rhinitis. The drug is a nasal aerosol corticosteroid.

May 10, 2011
Study: Allergy rhinitis symptoms linked to sleep disruption

Patients with seasonal allergies are more likely to experience difficulty sleeping, according to results of a new survey conducted by Teva Respiratory.

HORSHAM, Pa. — Patients with seasonal allergies are more likely to experience difficulty sleeping, according to results of a new survey conducted by Teva Respiratory.

March 22, 2011
Many nasal allergy sufferers don't have control over symptoms

Less than 20% of surveyed patients with nasal allergies find their symptoms are completely controlled over a one-week period of treatment, according to a survey performed by drug maker Teva Pharmaceutical Industries.

SAN FRANCISCO — Less than 20% of surveyed patients with nasal allergies find their symptoms are completely controlled over a one-week period of treatment, according to a survey performed by drug maker Teva Pharmaceutical Industries.

February 9, 2011
Teva's Qnaze meets endpoints in phase-3 trial

An investigational drug made by Teva Pharmaceutical Industries for treating allergies is safe and effective, according to results of a late-stage clinical trial announced Wednesday.

JERUSALEM — An investigational drug made by Teva Pharmaceutical Industries for treating allergies is safe and effective, according to results of a late-stage clinical trial announced Wednesday.

Teva said the phase-3 trial of the nasally inhaled drug Qnaze (beclomethasone dipropionate) showed that it significantly relieved symptoms of seasonal and perennial allergic rhinitis compared with placebo while demonstrating a similar safety profile.

November 15, 2010
Teva releases late-stage trial results for Qnaze HFA

An investigative treatment for allergies made by Teva Pharmaceutical Industries appears to work, according to...

JERUSALEM — An investigative treatment for allergies made by Teva Pharmaceutical Industries appears to work, according to results of a late-stage clinical trial released Monday.

 

Teva said phase-3 data from a study of Qnaze HFA (beclomethasone dipropionate), designed to be inhaled through the nose, was effective in treating patients with seasonal allergic rhinitis, while safety results were similar to those for placebo. Data from the study were presented at the annual meeting of the American College of Allergy, Asthma & Immunology in Phoenix.